THE WHAT? Dr. Stephen Hahn, a Donald Trump-nominated candidate, is one step closer to heading up the Food and Drug Administration with Senate lawmakers said to be ready to confirm the choice, according to the NY Times.
THE DETAILS? Hahn, a cancer specialist and medical executive at the MD Anderson Cancer Center in Houston, was voted in by a 18-5 majority of the Senate’s health committee. If appointed Hahn will succeed Dr. Scott Gottlieb who left the role in April 2019.
However, democrats are said to be opposed to the appointment due to his refusal to commit to a strong policy on vaping, with Hahn stating he would follow “data and science” rather than bow to political ideology.
THE WHY? The appointment of the head of the FDA will have direct consequences for many aspects of the U.S. cosmetics market, not least the appointed candidate will be faced with the onerous task of overseeing the regulation of the complex CBD market, amongst others.